Strength and recovery on a weight-loss plan

In their pivotal trials, semaglutide and tirzepatide led to 14.9% to 20.9% average weight loss. The same appetite shutdown that makes them work also pulls down your protein intake along with everything else, and some of what comes off is muscle.

Here’s our position up front: that isn’t a reason to skip the drug. It’s a reason to treat two cheap countermeasures, a daily protein floor and two short strength sessions a week, as part of the prescription from your very first shot instead of a rescue plan after a bad scan.

How much comes off, and what it’s made of

In STEP 1 (Wilding et al., NEJM 2021), 1,961 adults with obesity and no diabetes took brand-name semaglutide (Wegovy) 2.4 mg weekly or placebo. At week 68, the semaglutide group had lost 14.9% of their weight on average, compared with 2.4% on placebo.

In SURMOUNT-1 (Jastreboff et al., NEJM 2022), 2,539 adults were randomly assigned to brand-name tirzepatide (Zepbound) or placebo for 72 weeks. They lost 15.0% on 5 mg, 19.5% on 10 mg, and 20.9% on 15 mg, compared with 3.1% on placebo. For someone starting at 250 lbs, the top tirzepatide result comes to about 52 lbs, though that’s a trial average and doesn’t predict what you’ll lose.

The scale hides what the weight is made of. Losing weight costs some lean tissue no matter how you do it, and that’s normal physiology. But DXA substudies of the GLP-1 trials (body scans that split fat mass from lean mass) found that a real share of the loss was lean mass.

How big a share? The substudies are small next to their parent trials, and they give a range instead of one clean number. Two things follow from that. First, nothing about how the drug works protects muscle in particular. Second, how much muscle you lose depends on things you control.

Why protein is the first thing to go

The mechanism is settled. GLP-1 medicines slow gastric emptying (how fast your stomach empties), act on the appetite centers in your brain, and help your body release insulin. Tirzepatide also acts on a second receptor, called GIP. What you feel is that food sits longer, hunger drops, and meals shrink.

The problem is arithmetic. Muscle is maintained by two inputs, mechanical load and protein supply. The drug cuts your appetite for everything, so when your total intake falls, protein falls with it unless you defend it on purpose. Nobody craves chicken breast at 2.4 mg.

You know your hardest weeks ahead of time

Nausea is one of the most common side effects, and it tends to cluster during dose increases. That follows directly from delayed gastric emptying, which is why nausea tracks each dose step and fades when titration slows.

On the Wegovy label, semaglutide titration starts at 0.25 mg weekly and steps up about every 4 weeks: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg. On the fastest schedule you reach the full dose around week 16, and side effects can stretch that out, as they’re supposed to.

Treat that schedule like a training calendar. Your worst protein weeks come right after each dose increase, and you know those dates ahead of time. Mix up shakes before those weeks arrive, keep Greek yogurt, jerky, or whey within reach, and eat smaller amounts more often. Our quick high-protein meals list exists for exactly these weeks, and every entry hits at least 22 g without requiring an appetite.

This is also where clinician review earns its keep. At Zappy, a US-licensed clinician reviews every case and adjusts your titration. Holding a dose an extra month while your protein intake recovers is a better trade than racing to 2.4 mg underfed.

Zappy is cash-pay, with no insurance required, and you can use FSA or HSA funds. Our compounded semaglutide and tirzepatide are made by LegitScript-verified 503A US pharmacies. Compounded medicines are not FDA-approved.

The protein minimum: 1.2 to 1.6 grams per kilogram

Clinicians commonly target 1.2–1.6 g of protein per kilogram of body weight per day during GLP-1 treatment. That’s 96–128 g at 176 lbs (80 kg), and 120–160 g at 220 lbs (100 kg). It isn’t right for everyone, so let your clinician set your target, especially if you have kidney disease.

Spread it across three or four meals or snacks. 120 g is four servings of 30 g, which is about one Greek yogurt bowl, one shake, and two palm-sized portions of meat or fish. On a day when you’re not hungry, a shake can carry you.

That range is consensus practice. The reasoning behind it is strong, but no randomized trial picked it as the best one. The math also gets steep at higher body weights: at 264 lbs (120 kg), 1.6 g/kg is 192 g a day, which is a lot to ask of a suppressed appetite. That’s why the weight you base it on (current, adjusted, or goal) is a real medical choice.

Some clinicians calculate the target from adjusted body weight, which is your ideal weight plus 40% of the gap between your ideal and actual weight. Adjusted weight puts the same 1.2–1.6 g/kg range somewhere you can actually hit. The number changes as you do. Figure it out again after you’ve lost about 20 lbs. You don’t need to redo it every week.

Lifting: two sessions, four moves

Resistance training is the other half of the standard countermeasure, and we keep it boring on purpose: two 30-minute sessions a week, each covering a squat, a hinge (bending at the hips), a push, and a pull.

Bands and your own body weight count. A goblet squat, a hip hinge, push-ups against a counter, and a band row cover all four in your living room. You don’t need to lift heavy, but you do need to lift in the weeks you feel flat, which, as we said above, you can predict.

File it in the same tier as the protein floor: standard clinical practice built on how muscle is built and broken down. The pivotal trials tested the drugs and didn’t test the training, so we can’t tell you exactly how much lean mass two sessions a week preserves on semaglutide. We recommend it anyway, because it costs an hour a week and there’s no doubt about which way the biology points.

Recovery on a longer clock

The main trials ran 68 and 72 weeks. Staying at your new weight takes longer than that.

STEP 4 (Rubino et al., JAMA 2021) switched people off brand-name semaglutide (Wegovy) at week 20, and those who stopped regained a lot of weight compared with those who continued. Staying on the drug keeps the weight off, and stopping without a maintenance plan usually undoes the loss.

SURMOUNT-4 (Aronne et al., JAMA 2024) ran the same test with brand-name tirzepatide (Zepbound) and put numbers on it. After 36 weeks on the drug, people switched to placebo regained about 14% of their body weight over the next year, while those who continued lost about 5.5% more.

That changes how you should plan your training, because you’re choosing a routine you can still stand in year two. Pick boring and repeatable over perfect and fragile. If a joint hurts under weight, change the move. Don’t drop the habit.

Is the muscle loss a reason to skip the drug?

For people who qualify, no, as long as the protein and lifting actually happen. The benefits aren’t small. In SELECT (Lincoff et al., NEJM 2023), 17,604 adults with overweight or obesity and established cardiovascular disease, but no diabetes, took brand-name semaglutide (Wegovy) 2.4 mg or placebo. The drug lowered major heart events by 20% in relative terms (hazard ratio 0.80). Notice both limits: it’s a relative number, and it’s in people who already had heart disease. Don’t apply that number to everyone.

Here’s the part we’d rather not have to say. The drug won’t protect your muscle, and no clinic that sells it can eat your protein or do your lifting for you. If the protein and the two sessions aren’t going to happen, expect a smaller body that’s weaker than it needed to be. That’s a real cost, and it’s our job to tell you before you start.

What would change this advice? Evidence that lean-mass loss carries no cost to function, or that protein and lifting don’t change how much muscle you lose. The function half of that question hasn’t been studied yet, as we explain below.

How to know it’s working

A DXA scan is the same scan the trial substudies used, and it’s the cleanest way to track fat and lean mass. Lean mass isn’t all muscle, though. Ask your clinician whether a scan makes sense for you.

If you can’t, measure your waist weekly and your grip strength monthly with a cheap hand-grip meter (called a dynamometer). Those don’t replace a DXA scan, but they catch a bad trend early. A bad trend, with your waist flat and your grip falling, is exactly what to bring to your clinician. It argues for a slower next dose step and a harder look at your protein before anything else changes.

The short version

• Trial evidence: Brand-name semaglutide (Wegovy) led to 14.9% loss at 68 weeks (STEP 1). Brand-name tirzepatide (Zepbound) led to up to 20.9% at 72 weeks (SURMOUNT-1). Stopping brings the weight back (STEP 4, SURMOUNT-4). Brand-name semaglutide (Wegovy) lowered major heart events by 20% in relative terms in people who already had heart disease (SELECT). Body scan studies found a real share of the loss is lean tissue.
• Expert agreement, not proven in trials: Protein at 1.2–1.6 g/kg/day. Strength training twice a week. Slower dose steps when side effects hit.
• Our opinion: Figure out your protein minimum once. Stock up on shakes before every dose increase. Keep your lifting boring. Measure something every month.

The open question

A DXA scan counts kilograms of lean mass, but it doesn’t tell you whether you can carry groceries upstairs at 70. We don’t know the long-term effects of GLP-1 lean-mass loss on strength, mobility, or independence, especially in older adults.

The trial we really want hasn’t been run. It would randomly assign people starting a GLP-1 to structured strength training plus a protein floor, or to usual care, and then follow DXA scans and daily function for years. Until we have that, the countermeasures cost an hour a week and some Greek yogurt, which is cheap protection against a real unknown. We’re watching for that trial.